Common menu bar links

---

Table 1: Cases of potential lipodystrophy syndrome* associated with antiretroviral drugs reported to the CADRMP up to Aug. 31, 2001

---

Case	Age/ sex	Reported clinical  reactions†	Reported metabolic reactions†	Concomitant drugs	Duration of treatment	Suspect drug reported
						PI	NRTI
1	56/F	Lipodystrophy	Diabetes mellitus	Lamivudine, nadolol, Prevacid, Zoloft	NA	-	Stavudine
2	33/M	Fat disorder	Hyperglycemia	Lamivudine, stavudine	26 wk	Indinavir	-
3	44/M	Fat disorder	Hyperglycemia, hypertriglyceridemia	Nelfinavir	NA	Saquinavir	-
4	49/M	Lipodystrophy, enlarged abdomen	Hypertriglyceridemia	Azithromycin, lamivudine, saquinavir, stavudine	Continuing	Ritonavir	-

---

Note:

CADRMP = Canadian Adverse Drug Reaction Monitoring Program, PI = protease inhibitor, NRTI = nucleoside reverse transcriptase inhibitor, NA = not available.

* Met working case definition: at least one clinical feature and at least one metabolic abnormality, and no AIDS-defining event or other severe clinical illness or use of anabolic steroids, glucocorticoids or immune modulators within 3 months of assessment.

† Based on the "preferred term" of the World Health Organization Adverse Reaction Dictionary (WHOART).